Cilostazol and Aspirin in Stroke and TIA

Inclusion Criteria: * Diagnosis of an acute minor ischemic stroke or TIA * Acute minor stroke was defined by a score of 3 or less at the time of randomization on the National Institutes of Health Stroke Scale (NIHSS; scores range from 0 to 42, with higher scores indicating greater deficits) Exclusion Criteria: * Intracerebral Hemorrhage * Brain tumor * Brain abscess, or other major non-ischemic brain disease; * Isolated sensory symptoms (numbness, isolated visual changes, or isolated dizziness or vertigo) without evidence of acute infarction on baseline CT or MRI of the head * A score of more than 2 on the modified Rankin scale, immediately before the occurrence of the index ischemic stroke or TIA, indicating moderate disability or worse at baseline * An NIHSS score of 4 or more at randomization * A clear indication for anticoagulation therapy (presumed cardiac source of embolus, such as atrial fibrillation or prosthetic cardiac valve) or a contraindication to clopidogrel, cilostazol or aspirin * History of intracranial hemorrhage * Anticipated requirement for long-term non-study antiplatelet drugs or for nonsteroidal anti-inflammatory drugs affecting platelet function * Heparin therapy or oral anticoagulation therapy within 10 days before randomization * Gastrointestinal bleeding or major surgery within the previous 3 months * Planned or probable revascularization (any angioplasty or vascular surgery) within 3 months after screening (if clinically indicated, vascular imaging was to be performed before randomization, whenever possible) * Planned surgery or interventional treatment requiring cessation of the study drug * TIA or minor stroke caused by angiography or surgery * Severe non- cardiovascular coexisting condition, with a life expectancy of less than 3 months